Please assess the completion status of the following clinical trial:

Trial Title: IV Dosage Form of LCB01-0371 Phase I Study in Healthy Male Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy Male between 19 and 39 years of age at the time of screening~2. Subjects with body mass index (BMI) between 19 and 27 at the time of screening~3. Agree to continue to use a medically reliable dual contraception and not to donate sperm until 28 days of study completion~4. Capable of giving written informed consent, willing to participate in this clinical trial, and willing to comply with all study requirements~Exclusion Criteria:~1. History of gastrointestinal problem (e.g. Crohn's disease, gastro-intestinal ulcer) which is affect to absorption OR surgical history except appendectomy, herniotomy~2. History of allergy, cardiovascular, peripheral vascular, skin, mucous membrane, eyes, otorhinolaryngologic, respiratory, musculoskeletal, infectious disease, gastroenterologic, liver, billiary, endocrinologic, kidney, genitourinary, neuropsychiatric, hemato-oncologic problem(s) or fracture etc.

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: 39 Years
- Healthy Volunteers: t

Study Arms:
- LCB01-0371 200mg (Type: EXPERIMENTAL): LCB01-0371 IV 200 mg
- LCB01-0371 400mg (Type: EXPERIMENTAL): LCB01-0371 IV 400 mg
- LCB01-0371 800mg (Type: EXPERIMENTAL): LCB01-0371 IV 800 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).